NCT03397654View on ClinicalTrials.gov

Study of Pembrolizumab Following TACE in Primary Liver Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 28, 2018

Primary Completion Date

February 1, 2023

Study Completion Date

March 23, 2023

Conditions

Primary Liver Carcinoma

Interventions

DRUG

Pembrolizumab

Pembrolizumab solution

COMBINATION_PRODUCT

Trans-arterial chemoembolization

Doxorubicin injected through the hepatic blood supply directly to the cancer-affected part of the liver, then gelatin sponge particles injected to block the blood vessels supplying the tumour

Trial Locations (1)

Unknown

Imperial College Healthcare NHS Trust, London

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Imperial College London

OTHER

NCT03397654 - Study of Pembrolizumab Following TACE in Primary Liver Carcinoma | Biotech Hunter | Biotech Hunter